Beware fingolimod discontinuation

The rationale for prescribing fingolimod in relapse-remitting multiple sclerosis needs a rethink, say US researchers.  

Neurologists from the University of California have reported on the cases of five women receiving treatment who experienced a severe rebound effect after discontinuing the drug.

In all cases, the women developed several new lesions within 4-16 weeks after stopping